日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT

德国CARAT研究平台基于真实世界数据,对晚期肾细胞癌一线治疗策略中TKI和CPI的疗效进行了直接比较。

Goebell, Peter J; Bögemann, Martin; Nusch, Arnd; Grünwald, Viktor; Müller, Lothar; von der Heyde, Eyck; Martens, Uwe M; Lennartz, Carolin; Koska, Michaela; Potthoff, Karin; Kaiser-Osterhues, Anja; Grüllich, Carsten; Staehler, Michael; Jänicke, Martina; Marschner, Dominik

Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis

更正:替沃扎尼单药一线治疗预后良好的转移性肾细胞癌患者

Frazer, Ricky; Arranz, José Ángel; Estévez, Sergio Vázquez; Parikh, Omi; Krabbe, Laura-Maria; Vasudev, Naveen S; Doehn, Christian; Marschner, Norbert; Waddell, Tom; Ince, Will; Goebell, Peter J

Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review

转移性激素敏感性前列腺癌患者接受雄激素剥夺疗法强化治疗的实际应用:系统评价

Raval, Amit D; Chen, Stephanie; Littleton, Natasha; Constantinovici, Niculae; Goebell, Peter J

Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations

在综合癌症中心,通过肿瘤专科医生第二诊疗意见提高癌症患者的护理质量:对第二诊疗意见治疗建议的依从性

Schulmeyer, Carla; Fasching, Peter A; Beckmann, Matthias W; Häberle, Lothar; Golcher, Henriette; Goebell, Peter J; Pöschke, Patrik; Emons, Julius

Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK

转移性激素敏感性前列腺癌的当代真实世界治疗:美国、四个欧洲国家和英国

Goebell, Peter J; Chen, Stephanie; Jhaveri, Jay

A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

TROPiCS-04 研究的简明语言摘要:在接受铂类化疗和免疫治疗后,使用 sacituzumab govitecan 治疗局部晚期或转移性膀胱癌、尿道癌或上尿路癌患者。

Powles, Thomas; Tagawa, Scott T; Vulsteke, Christof; Gross-Goupil, Marine; Park, Se Hoon; Necchi, Andrea; De Santis, Maria; Duran, Ignacio; Morales-Barrera, Rafael; Guo, Jun; Sternberg, Cora N; Bellmunt, Joaquim; Goebell, Peter J; Kovalenko, Maria; Boateng, Freda; Sierecki, Mitch; Wang, Lu; Sima, Camelia S; Waldes, Jana; Bangs, Rick; Loriot, Yohann; Grivas, Petros

Effect of Recipient Variables on Transplant Survival Following Marginal Kidney Donation: Analysis of a Mate Kidney Cohort

受者变量对边缘肾脏捐献后移植存活率的影响:一项配对肾脏队列研究分析

Androvitsanea, Ariadni; Heller, Katharina M; Apel, Hendrik; Kunath, Frank; Goebell, Peter J; Wullich, Bernd; Rother, Ulrich; Daniel, Christoph; Amann, Kerstin; Willam, Carsten; Schiffer, Mario

Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)

在真实世界环境中,基于 GnRH 激动剂的雄激素剥夺疗法的心血管安全性:一项前瞻性队列研究 (LEAN) 的结果

Schmitz-Dräger, Bernd J; Schmitz-Dräger, Bernd J; Bismarck, Ekkehardt; Ebert, Thomas; Starlinger, Roland; Dienes, Kerstin; Ottillinger, Bertram; Goebell, Peter J; Mühlich, Stephan; Benderska-Söder, Natalya; Bergler-Klein, Jutta; Hakenberg, Oliver W

[PSA in the extreme range-an expression of an unfavorable prognosis? : A review of course and treatment of prostate cancer with prostate-specific antigen (PSA) values in the three-to-four-digit range]

[PSA值处于极端范围——是否预示着不良预后?:前列腺特异性抗原(PSA)值在三位数至四位数范围内的前列腺癌的病程和治疗综述]

Dirscherl, Christian; Ebert, Thomas; Schmitz-Dräger, Bernd J; Goebell, Peter J

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis

替沃扎尼单药一线治疗预后良好的转移性肾细胞癌患者

Frazer, Ricky; Arranz, José Ángel; Estévez, Sergio Vázquez; Parikh, Omi; Krabbe, Laura-Maria; Vasudev, Naveen S; Doehn, Christian; Marschner, Norbert; Waddell, Tom; Ince, Will; Goebell, Peter J